{"id":1336,"date":"2020-10-08T11:55:06","date_gmt":"2020-10-08T09:55:06","guid":{"rendered":"https:\/\/pharmavalue.it\/?p=1336"},"modified":"2022-02-17T12:05:35","modified_gmt":"2022-02-17T11:05:35","slug":"summary-of-oms-guidelines-on-drug-pricing-policies","status":"publish","type":"post","link":"https:\/\/pharmavalue.it\/en\/summary-of-oms-guidelines-on-drug-pricing-policies\/","title":{"rendered":"Summary of the WHO Guidelines on Drug Pricing Policies"},"content":{"rendered":"<p>On 28 September 2020, the WHO published a document entitled \"<em><span style=\"font-weight: 400;\">WHO guideline on country pharmaceutical pricing policies<\/span><\/em>\".<\/p>\n<p>The document on WHO pricing policies contains several references to the Transparency Resolution sent to WHO by Giulia Grillo (Former Minister of Health) and Luca Li Bassi (Former Director General of AIFA), which was approved at the 72nd World Health Assembly in 2019.<\/p>\n<p>There are 10 key policy points in terms of drug pricing that represent the evidence and recommendations of the WHO.<\/p>\n<p>Here is our summary (in Italian) of the document<\/p>\n<div class=\"_df_book df-lite\" id=\"df_1339\"  _slug=\"1339\" data-title=\"sintesi-delle-linee-guida-oms-sulle-politiche-dei-prezzi-dei-farmaci\" wpoptions=\"true\" thumbtype=\"\" ><\/div><script class=\"df-shortcode-script\" nowprocket type=\"application\/javascript\">window.option_df_1339 = {\"outline\":[],\"backgroundColor\":\"#eeeeee\",\"duration\":\"500\",\"autoEnableOutline\":\"false\",\"autoEnableThumbnail\":\"false\",\"overwritePDFOutline\":\"false\",\"enableDownload\":\"true\",\"direction\":\"1\",\"pageSize\":\"0\",\"soundEnable\":\"false\",\"source\":\"https:\\\/\\\/pharmavalue.it\\\/wp-content\\\/uploads\\\/2021\\\/04\\\/Sintesi-delle-Linee-Guida-OMS-sulle-politiche-dei-prezzi-dei-farmaci_S1.pdf\",\"wpOptions\":\"true\"}; if(window.DFLIP && window.DFLIP.parseBooks){window.DFLIP.parseBooks();}<\/script>","protected":false},"excerpt":{"rendered":"<p>Il 28 Settembre 2020 l\u2019OMS ha pubblicato un documento dal titolo &#8220;WHO guideline on country pharmaceutical pricing policies\u201d. Il documento sulle politiche di prezzo dell\u2019OMS contiene diversi riferimenti alla Transparency Resolution inviata all\u2019OMS da Giulia Grillo (Ex Ministro della Salute) e Luca Li Bassi (EX Direttore Generale di AIFA), approvata nella 72\u00b0 Assemblea Mondiale della [&hellip;]<\/p>\n","protected":false},"author":314,"featured_media":1338,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"none","_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"","footnotes":""},"categories":[9],"tags":[37,36],"class_list":["post-1336","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-appunti","tag-oms","tag-prezzo-dei-farmaci"],"_links":{"self":[{"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/posts\/1336","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/users\/314"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/comments?post=1336"}],"version-history":[{"count":0,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/posts\/1336\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/media\/1338"}],"wp:attachment":[{"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/media?parent=1336"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/categories?post=1336"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/tags?post=1336"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}